Voluntary isn't working
By Marcy Darnovsky,
Modern Healthcare
| 04. 13. 2009
Recent events show need for regulation of assisted reproduction
Each year, assisted reproduction quietly helps thousands of people in their quest for children biologically related to them. But the fertility field has been far from quiet of late. In recent weeks, two scandals burst into the headlines
The first stories about the Southern California octuplets, in late January, focused on the novelty and details of their birth. But shock and then outrage quickly followed as news of the mother's circumstances and the fertility doctor's recklessness emerged. Entertainment news has yet to tire of the story; a more sober conversation about the need for additional policy and oversight is also simmering.
A few weeks later, the Wall Street Journal reported that another Los Angeles-area fertility clinic had begun advertising the "pending availability" of embryo screening to select for hair color, eye color and even skin tone. As that story bubbled into network and cable news, it elicited a reaction similar to the one surrounding the octuplets: What's going on here? How can irresponsible fertility doctors get away with this sort of thing?
These questions are not being asked only by...
Related Articles
By Grace Won, KQED [with CGS' Katie Hasson] | 12.02.2025
In the U.S., it’s illegal to edit genes in human embryos with the intention of creating a genetically engineered baby. But according to the Wall Street Journal, Bay Area startups are focused on just that. It wouldn’t be the first...
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Emily Glazer, Katherine Long, Amy Dockser Marcus, The Wall Street Journal | 11.08.2025
For months, a small company in San Francisco has been pursuing a secretive project: the birth of a genetically engineered baby.
Backed by OpenAI chief executive Sam Altman and his husband, along with Coinbase co-founder and CEO Brian Armstrong, the startup—called...
By Antonio Regalado, MIT Technology Review | 10.31.2025
A West Coast biotech entrepreneur says he’s secured $30 million to form a public-benefit company to study how to safely create genetically edited babies, marking the largest known investment into the taboo technology.
The new company, called Preventive, is...